Strut in 2026: the short version
Strut Health, LLC is a Dallas-based telehealth company that originally built its business on compounded men's health products — erectile dysfunction medications, hair loss treatments, and testosterone support — and later expanded into compounded GLP-1 weight loss. CEO Simal Patel, MD runs the operation from 701 Commerce Street in downtown Dallas.
On February 20, 2026, the FDA's Center for Drug Evaluation and Research issued Strut warning letter #721448 as part of the agency's broader compounded GLP-1 enforcement action that month. Strut is one of three warning letters that industry attorneys have described as "representative" of the FDA's enforcement focus, alongside letters to SkinnyRx and Newman Clinic.
Strut is not a standout villain in this story — the issues the FDA flagged are consistent across the category. But if you are evaluating Strut for a compounded GLP-1 in April 2026, the warning letter is a material fact you deserve to know about.
This review is an independent editorial assessment. It contains affiliate links to Strut Health and to alternative providers. Compounded medications are not FDA-approved as finished products. Receiving an affiliate commission does not influence our assessment.
What the FDA warning letter actually says
Warning letter #721448, addressed to Simal Patel, MD, reviews content the FDA observed on struthealth.com in December 2025 and identifies two categories of alleged violation:
1. The "Strut" label on compounded vials
The FDA specifically noted that compounded semaglutide and tirzepatide product images on Strut's website showed vials whose labels read "Strut" — implying that Strut itself was the compounder. Under federal labeling regulations (21 CFR § 201.1(h)(2)), that labeling misrepresents the actual manufacturer. Strut does not operate a compounding pharmacy; the actual compounders are third-party 503A pharmacies that Strut's prescriptions route to.
2. Marketing language implying FDA approval
The second category involves website language that, in the FDA's reading, suggested the compounded semaglutide and tirzepatide products had been "FDA-approved or otherwise evaluated for safety and effectiveness." The reality is that compounded medications are prepared for individual prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act and are explicitly not FDA-approved as finished products.
The letter demanded a written response within 15 working days describing specific corrective steps. Strut, like other recipients, would have been expected to update website copy, remove branded product images, and confirm labeling practices with its compounding pharmacy partners.
The FDA warning letter is not unique to Strut. In March 2026, the FDA issued warning letters to more than 30 additional telehealth companies for similar marketing violations. According to STAT News reporting, at least 30% of the companies shared clinical ties to just four nationwide medical groups. This is a category-wide enforcement action, not a targeted investigation.
What Strut offers
Strut's product line spans three categories: men's sexual health (compounded ED formulations and related products), hair loss treatments (finasteride/minoxidil topicals and combinations), and compounded GLP-1 weight loss (semaglutide and tirzepatide, primarily injectable with some oral options). The company runs asynchronous telehealth consultations — you complete an intake form, a licensed clinician reviews it, and if approved, a prescription routes to a partner pharmacy.
Strut's clinical model is fairly standard for the telehealth category. What distinguishes Strut from pure GLP-1 specialists is its diversified product mix; weight loss is one of several programs, not the entire business. That may or may not matter to you, but it does mean Strut has operational experience across multiple compounding categories.
Pricing and program structure
Strut's GLP-1 pricing has shifted multiple times in 2026. Current published starting prices tend to sit in the $199–$299 per month range for compounded semaglutide depending on dose tier, with tirzepatide priced higher. Verify current pricing on the Strut Health website before enrolling.
| Category | Typical starting price | Notes |
|---|---|---|
| Compounded semaglutide | $199–$249/mo | Dose-based; steps up with titration |
| Compounded tirzepatide | $299–$399/mo | Dose-based; limited lower-dose availability |
| ED products | $20–$60/mo | Not GLP-1 related |
| Hair loss (topical) | $20–$40/mo | Not GLP-1 related |
Billing is monthly on a rolling cycle. Cancellation is available through the patient portal or by contacting support, though specific terms depend on which program you have enrolled in.
Strengths and concerns
Strengths
- Operates across multiple telehealth categories (not a GLP-1-only operation)
- Texas-based with physical offices and identifiable medical leadership
- Reasonably fast intake and prescription turnaround
- Clinician-supervised prescribing model
- Diversified revenue — less existential risk from a single category
Concerns
- Active February 2026 FDA warning letter for misbranding
- Compounded medications are not FDA-approved as finished products
- Pricing lands mid-pack — not a cost leader
- Limited public disclosure of which compounding pharmacy fills each prescription
- No published third-party clinical outcomes data
Alternatives worth comparing
For most people researching oral GLP-1 options in 2026, the decision is not "Strut or no GLP-1" — it is "which provider gives me the cleanest paper trail and the best regulatory standing for my specific situation."
Sesame Care — FDA-approved brand-name path
Sesame Care is a Novo Nordisk Recognized Care Provider. Through Sesame you can access clinician consultations and prescriptions for FDA-approved brand-name Wegovy pill, Rybelsus, or Foundayo — not compounded alternatives. This is the regulatory gold standard.
SHED — compounded without the warning letter
SHED did not receive a warning letter in February 2026. LegitScript certified, widest oral format variety (tablet, ODT, lozenge), and transparent about which 503A compounding pharmacy fills each prescription. If you are committed to a compounded route, this is our top pick. Compounded medications are not FDA-approved.
Our bottom line on Strut
Strut Health is an established telehealth operator with a credible business outside GLP-1s and a clinician-led structure. It is not a fly-by-night operation. The February 2026 warning letter is a real issue, but it is also a category-wide issue, and Strut's violations as alleged were not unusual relative to peers.
That said, for a new enrollment in April 2026, we do not see a compelling reason to choose Strut specifically. Sesame Care gives you the FDA-approved brand-name path. SHED gives you a better-documented compounded path without an active warning letter. Strut falls in between on regulatory standing and does not lead on price. Existing customers have less reason to switch immediately, but new enrollees should start with alternatives.
Did Strut respond to the FDA warning letter?
The warning letter demanded a response within 15 working days of receipt. Strut's response, if filed, is not publicly visible unless the FDA subsequently posts a closeout letter or takes further enforcement action. No public closeout has been posted as of this writing.
Are Strut's ED and hair products affected by the warning letter?
The February 2026 warning letter addressed compounded semaglutide and tirzepatide specifically. It did not cite Strut's ED or hair loss products. That said, any FDA enforcement action against a company is relevant context when evaluating any program from that company.
Is my Strut prescription still legal?
Yes. A warning letter is an enforcement communication addressed to the company, not a revocation of individual prescriptions or pharmacy dispensing licenses. Your medication, if filled by a licensed pharmacy, remains a valid prescription. The FDA's concerns are about marketing and labeling, not the clinical validity of individual prescriptions.
Should I switch providers?
That is a decision to make with your clinician based on how your current program is working for you. For new enrollments, we recommend starting with Sesame Care (brand-name) or SHED (compounded) over Strut. For existing Strut customers who are satisfied, a conservative approach is to continue current treatment while monitoring whether Strut's FDA situation progresses to a closeout or to further enforcement.